The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration

Tanaka, Nobumichi; Fujimoto, Kiyohide; Hirayama, Akihide; Samma, Shoji; Momose, Hitoshi; Kaneko, Yoshiteru; Haramoto, Masaki; Hayashi, Yoshiki; Nakagawa, Yasuaki; Otani, Takeshi; Watanabe, Shuji; Hirao, Yoshihiko

doi:10.1186/1471-2490-11-6

Cited by 10 publications

(14 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radical prostatectomy is selected as the initial therapy in 44% of American men with prostate cancer (PCa) [ 1 ]. Our data from Nara Uro-Oncological Research Group (NUORG) in Japan show an RP rate of approximately 30% (40% in stage cT1-2N0M0) with rates of radiation therapy, [ 2 ] but the proportion of radiation therapy is increasing [ 3 , 4 ]. In case of stage cT1-2N0M0 PCa, the corresponding figure was 40%es.…”

Section: Introductionmentioning

confidence: 99%

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundTreatment options for patients with recurrent disease after radical prostatectomy include salvage radiotherapy of the prostatic bed and/or androgen deprivation therapy. To establish an effective treatment strategy for recurrent disease after radical prostatectomy, we retrospectively analyzed the outcome of salvage radiation monotherapy in such cases.MethodsData from 61 men who had undergone salvage radiation monotherapy for biochemical recurrent disease after radical prostatectomy were retrospectively reviewed. In all patients, salvage radiotherapy consisted of iraradiation to the prostatic bed (70 Gy) using three-dimensional conformal radiotherapy techniques. Treatment outcome was analyzed to identify predictive factors of salvage radiotherapy.ResultsThe biochemical recurrence-free survival after salvage radiation monotherapy at 2 and 5 years was 55% and 38%, respectively. Cox proportional regression models revealed that the independent predictive factors for biochemical recurrence were Gleason Score ≥ 8, negative surgical margin, and PSA velocity ≥ 0.38 ng/mL/year. Negative surgical margin and PSA velocity ≥ 0.8 ng/mL/year were significantly associated with poor response in the serum PSA levels after salvage radiotherapy.ConclusionsBased on our findings, we propose a treatment strategy for biochemical recurrent disease after radical prostatectomy. Patients with Gleason score ≤ 7, positive surgical margin, and PSA velocity < 0.38 ng/mL/year are categorized the most favorable group, so that eradication by salvage radiation monotherapy could be expected. Other patients could be divided to two groups depending on surgical margin status and PSA velocity: 1) patients who might require combination of SRT and short-term androgen deprivation therapy and 2) patients who should be treated by androgen deprivation monotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…For localized disease, no randomized study has compared the effectiveness of the three treatment modalities – ie, radical prostatectomy, radiotherapy, and hormonal treatment – and existing evidence does not support superiority of one modality over the others 20. Therefore, patients’ preference for treatment modality and clinical consideration of patients’ age and predictive/biological characteristics are very important in determining the treatment of choice in patients with localized prostate cancer 21,22…”

Section: Introductionmentioning

confidence: 99%

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

Wex¹,

Sidhu²,

Odeyemi³

et al. 2013

CEOR

View full text Add to dashboard Cite

ObjectiveLeuprolide is an established luteinizing hormone–releasing hormone (LHRH) agonist used as first-line treatment in advanced prostate cancer. As different formulations and dosing schedules are likely to have economic implications, we aimed to evaluate their efficacy, safety, and costs in nine European countries: Austria, Belgium, Czech Republic, Hungary, Italy, Latvia, Netherlands, Poland, and Portugal.MethodsDatabase searches identified 13 clinical trials of leuprolide 1- (1 M), 3- (3 M) and 6-monthly (6 M). Only data on leuprolide with Atrigel were compared for all three formulations, which had the same efficacy, safety, and adherence. Cost-minimization analysis accounting for cost of Eligard®, specialist consultations, and diagnostics during up to 12 months follow-up was conducted. The perspective was that of public payers.ResultsNo significant differences were observed in the percentages of intention-to-treat patients achieving testosterone levels ≤ 50 ng/dL following treatment with Eligard® 1 M (93.3%), 3 M (98.3%), and 6 M (97.3%) (P > 0.05), and adverse event profiles of the three formulations were comparable. Overall, 6 M was the least expensive, with average total annual costs from €788 (Belgium) to €1839 (Portugal). The 3 M option was between 2.5% (Hungary) and 37.6% (Belgium) more expensive than 6 M; 1 M formulation was the most expensive, with costs 15.5% and 151.6% more expensive than 6 M for those countries, respectively. The 3 M option was 11.2%–45.3% less expensive than 1 M. Total costs were associated with frequency of visits for injection and monitoring. The 1 M required twelve visits, 3 M 4.4–4.8 visits, and 6 M 2.1–2.3 visits. Up to 50% additional visits could be funded with the savings resulting from switching eligible patients from 1 M and 3 M to 6 M. Results were stable in univariate and probabilistic sensitivity analyses.ConclusionEligard® formulations offer comparable efficacy and safety, but different dosing schedules require different number of visits. The 6 M formulation offers the greatest cost savings and should be considered the treatment of choice in eligible patients in Europe.

show abstract

“…JAPAN Y.H. (Nara Medical University, Kashihara City, Nara, Japan) reported results of a study evaluating the distribution of primary therapy and clinical characteristics of over 2000 prostate cancer patients at Nara Medical University and its 23 affiliated hospitals (25). The study had also investigated the differences between the preferential primary therapy conceived by the primary doctors and the primary therapy actually administered for prostate cancer patients.…”

mentioning

confidence: 99%

Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management

Akaza

Carroll

Cooperberg

et al. 2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

This report summarizes the presentations and discussions that took place at the Fifth Joint Meeting of J-CaP and CaPSURE held in Tokyo, Japan, in July 2011. The J-CaP and CaPSURE Joint Initiative was established in 2007 with the objective of analyzing, reviewing, comparing and contrasting data on prostate cancer patients from Japan and the USA within the two important large-scale, longitudinal, observational databases-J-CaP and CaPSURE. Since its inception, the initiative has reviewed a wide range of topics and generated valuable data on the patterns of prostate cancer treatment and patient outcomes in the two geographical regions. The objectives of this 5th Joint Meeting were to provide an update on the current status of the J-CaP and CaPSURE databases, and also to discuss perspectives from a range of other Asian countries-Japan, China, Indonesia and Korea-on the use of androgen deprivation therapy for prostate cancer. The collaborators recognize that large databases, such as J-CaP and CaPSURE, provide valuable 'real-world' information, to complement data from clinical trials, which can help to advance the clinical management of prostate cancer patients worldwide. It is anticipated that in the near future, the Joint Initiative will expand globally to include patient registries from other countries so that best practice can be shared and regional differences in patients, treatments and outcomes can be explored.

show abstract

The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration

Cited by 10 publications

References 15 publications

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management

Contact Info

Product

Resources

About